Pharmacogenomic of LH and its receptor: are we ready for clinical practice?
Abstract Luteinizing hormone (LH) is fundamental to support development and reproduction. It acts through a receptor expressed in the gonads, modulating mitogenic, anti-apoptotic, and steroidogenic signals. LH is also marketed as a drug for controlled ovarian stimulation (COS), where it is administe...
Saved in:
| Main Authors: | Alessandro Conforti, Raffaella Di Girolamo, Maurizio Guida, Carlo Alviggi, Livio Casarini |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-02-01
|
| Series: | Reproductive Biology and Endocrinology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12958-025-01359-2 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Impact of gonadotropin genetic profile and ovarian reserve on controlled ovarian stimulation: data from prospective cohort of the GENOCS trial
by: Alessandro Conforti, et al.
Published: (2025-08-01) -
The role of recombinant LH in ovarian stimulation: what’s new?
by: Carlo Alviggi, et al.
Published: (2025-03-01) -
Surfing follicular waves in ovarian stimulation: is there a role for LH in DuoStim protocols? A narrative review and SWOT analysis
by: Alberto Vaiarelli, et al.
Published: (2025-02-01) -
LH level on trigger day, number of follicles ≥16 mm but <18 mm, and number of retrieved oocytes are independent risk factors for polyspermy in gonadotropin-releasing hormone antagonist protocol
by: Qiongyu Wu, et al.
Published: (2024-12-01) -
Significance of FSHR and LHCGR gene polymorphisms on clinical outcomes in gonadotropin-releasing hormone antagonist protocol with freeze-all strategy: A case-control study
by: Jayesh Amin, et al.
Published: (2024-09-01)